Hypercortisolism Found in 27.3% of Resistant Hypertension Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy CORT?
Source: Yahoo Finance
- Study Findings: Among 1,086 patients with resistant hypertension meeting American Heart Association criteria, 27.3% (297 patients) were diagnosed with hypercortisolism, complementing Corcept's CATALYST trial which found 23.8% in 1,057 patients with difficult-to-control type 2 diabetes.
- High-Risk Warning: Patients with resistant hypertension face increased risks of cardiovascular events such as heart attacks, strokes, and kidney damage, with hypercortisolism contributing to over a quarter of these cases, underscoring the importance of screening for better personalized treatment options.
- Clinical Research Presentation: At the 2026 American College of Cardiology Annual Scientific Session, Dr. Deepak L. Bhatt presented MOMENTUM trial data, highlighting the prevalence of hypercortisolism in resistant hypertension patients, which may drive further research and screening efforts.
- Company Strategy: Corcept Therapeutics aims to leverage MOMENTUM trial findings to enhance screening and diagnosis of hypercortisolism, improving treatment options and solidifying its market position in endocrine disorder therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CORT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CORT
Wall Street analysts forecast CORT stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 37.600
Low
50.00
Averages
91.00
High
121.00
Current: 37.600
Low
50.00
Averages
91.00
High
121.00
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should note that the deadline to apply as lead plaintiff is April 21, 2026, after which they will lose their right to participate.
- Fee Arrangement: Investors joining the Corcept class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial burdens and encouraging broader participation in the lawsuit.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and expertise, which investors should consider when selecting legal counsel.
- FDA Regulatory Risks: The lawsuit alleges that Corcept misrepresented the clinical trial support for its relacorilant NDA, leading to investor losses when the truth emerged, highlighting significant risks and uncertainties in the company's drug approval process.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 31, 2024, and December 30, 2025.
- False Statements: The complaint alleges that Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, claiming it was 'approaching approval' while knowing the FDA deemed its clinical data inadequate for approval.
- Investor Losses: When the market learned the truth about Corcept, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm encourages investors who purchased Corcept securities during the class period to contact them before April 21, 2026, to discuss their rights and participate in the lawsuit to seek compensation for their losses.
See More
Reminder for Corcept Therapeutics Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the strong support from FDA for the NDA of relacorilant, while in reality, the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure optimal representation in the lawsuit and avoid inexperienced intermediaries.
See More
Discovery of Hypercortisolism in Resistant Hypertension Patients
- Study Overview: At the 2026 American College of Cardiology Annual Scientific Session (ACC 2026), Corcept Therapeutics presented data from the MOMENTUM trial, revealing that 27.3% (297 patients) of 1,086 individuals with resistant hypertension were found to have endogenous hypercortisolism, providing new insights for personalized treatment of hypertension.
- Diabetes Correlation: The findings from MOMENTUM complement those of the CATALYST trial, which identified hypercortisolism in 23.8% of 1,057 patients with difficult-to-control type 2 diabetes, indicating a higher prevalence of hypercortisolism in patients with elevated blood sugar and underscoring the importance of screening these individuals.
- Clinical Significance: The research indicates that hypercortisolism's prevalence among resistant hypertension patients may increase the risk of cardiovascular events such as heart attacks and strokes, highlighting the necessity for screening to provide more personalized medical care for these challenging cases.
- Future Research Directions: Corcept's Chief Development Officer, Bill Guyer, noted that the prevalence of hypercortisolism is greater than previously assumed, and the company will continue to advocate for improved screening and treatment options to enhance patient quality of life and treatment outcomes.
See More
Hypercortisolism Found in 27.3% of Resistant Hypertension Patients
- Study Findings: Among 1,086 patients with resistant hypertension meeting American Heart Association criteria, 27.3% (297 patients) were diagnosed with hypercortisolism, complementing Corcept's CATALYST trial which found 23.8% in 1,057 patients with difficult-to-control type 2 diabetes.
- High-Risk Warning: Patients with resistant hypertension face increased risks of cardiovascular events such as heart attacks, strokes, and kidney damage, with hypercortisolism contributing to over a quarter of these cases, underscoring the importance of screening for better personalized treatment options.
- Clinical Research Presentation: At the 2026 American College of Cardiology Annual Scientific Session, Dr. Deepak L. Bhatt presented MOMENTUM trial data, highlighting the prevalence of hypercortisolism in resistant hypertension patients, which may drive further research and screening efforts.
- Company Strategy: Corcept Therapeutics aims to leverage MOMENTUM trial findings to enhance screening and diagnosis of hypercortisolism, improving treatment options and solidifying its market position in endocrine disorder therapies.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics received FDA approval for its cancer drug Lifyorli, allowing it to be used in combination with nab-paclitaxel for treating platinum-resistant fallopian tube, primary peritoneal, and ovarian cancers, marking a significant advancement in the company's oncology portfolio.
- Stock Price Surge: Following the FDA approval announcement, Corcept's stock experienced a nearly 9% increase over the week, although some investors took quick profits, indicating strong market confidence in the company's growth potential driven by its new drug.
- Analyst Rating Upgrade: Wolfe Research analyst Kalpit Patel upgraded Corcept's rating from underperform to peerperform, primarily based on the FDA approval, although he remains cautious about the growth potential of its other drug, Korlym, reflecting a nuanced view of the company's product lineup.
- Market Potential Outlook: The success of Lifyorli not only provides Corcept with a marketable drug but also validates its unique development approach, particularly in the high-demand cancer treatment sector, potentially laying a solid foundation for future growth.
See More
Corcept Therapeutics Class Action Reminder for Investors
- Lawsuit Timeline: Investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, should note that the deadline to apply as lead plaintiff is April 21, 2026, after which they will lose their right to participate.
- Fee Arrangement: Investors joining the Corcept class action will incur no out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby reducing financial burdens and encouraging broader participation in the lawsuit.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong track record and expertise, which investors should consider when selecting legal counsel.
- FDA Regulatory Risks: The lawsuit alleges that Corcept misrepresented the clinical trial support for its relacorilant NDA, leading to investor losses when the truth emerged, highlighting significant risks and uncertainties in the company's drug approval process.
See More
Corcept Therapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Corcept Therapeutics (NASDAQ:CORT) for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 31, 2024, and December 30, 2025.
- False Statements: The complaint alleges that Corcept made false and misleading statements regarding the viability of its product candidate, relacorilant, claiming it was 'approaching approval' while knowing the FDA deemed its clinical data inadequate for approval.
- Investor Losses: When the market learned the truth about Corcept, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm encourages investors who purchased Corcept securities during the class period to contact them before April 21, 2026, to discuss their rights and participate in the lawsuit to seek compensation for their losses.
See More
Reminder for Corcept Therapeutics Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Corcept Therapeutics (NASDAQ: CORT) common stock between October 31, 2024, and December 30, 2025, to apply as lead plaintiffs by April 21, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Corcept made false statements regarding the strong support from FDA for the NDA of relacorilant, while in reality, the FDA had raised concerns about the adequacy of clinical evidence, exposing investors to significant risks.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure optimal representation in the lawsuit and avoid inexperienced intermediaries.
See More
Discovery of Hypercortisolism in Resistant Hypertension Patients
- Study Overview: At the 2026 American College of Cardiology Annual Scientific Session (ACC 2026), Corcept Therapeutics presented data from the MOMENTUM trial, revealing that 27.3% (297 patients) of 1,086 individuals with resistant hypertension were found to have endogenous hypercortisolism, providing new insights for personalized treatment of hypertension.
- Diabetes Correlation: The findings from MOMENTUM complement those of the CATALYST trial, which identified hypercortisolism in 23.8% of 1,057 patients with difficult-to-control type 2 diabetes, indicating a higher prevalence of hypercortisolism in patients with elevated blood sugar and underscoring the importance of screening these individuals.
- Clinical Significance: The research indicates that hypercortisolism's prevalence among resistant hypertension patients may increase the risk of cardiovascular events such as heart attacks and strokes, highlighting the necessity for screening to provide more personalized medical care for these challenging cases.
- Future Research Directions: Corcept's Chief Development Officer, Bill Guyer, noted that the prevalence of hypercortisolism is greater than previously assumed, and the company will continue to advocate for improved screening and treatment options to enhance patient quality of life and treatment outcomes.
See More
Hypercortisolism Found in 27.3% of Resistant Hypertension Patients
- Study Findings: Among 1,086 patients with resistant hypertension meeting American Heart Association criteria, 27.3% (297 patients) were diagnosed with hypercortisolism, complementing Corcept's CATALYST trial which found 23.8% in 1,057 patients with difficult-to-control type 2 diabetes.
- High-Risk Warning: Patients with resistant hypertension face increased risks of cardiovascular events such as heart attacks, strokes, and kidney damage, with hypercortisolism contributing to over a quarter of these cases, underscoring the importance of screening for better personalized treatment options.
- Clinical Research Presentation: At the 2026 American College of Cardiology Annual Scientific Session, Dr. Deepak L. Bhatt presented MOMENTUM trial data, highlighting the prevalence of hypercortisolism in resistant hypertension patients, which may drive further research and screening efforts.
- Company Strategy: Corcept Therapeutics aims to leverage MOMENTUM trial findings to enhance screening and diagnosis of hypercortisolism, improving treatment options and solidifying its market position in endocrine disorder therapies.
See More
Corcept Therapeutics Receives FDA Approval for Lifyorli
- FDA Approval: Corcept Therapeutics received FDA approval for its cancer drug Lifyorli, allowing it to be used in combination with nab-paclitaxel for treating platinum-resistant fallopian tube, primary peritoneal, and ovarian cancers, marking a significant advancement in the company's oncology portfolio.
- Stock Price Surge: Following the FDA approval announcement, Corcept's stock experienced a nearly 9% increase over the week, although some investors took quick profits, indicating strong market confidence in the company's growth potential driven by its new drug.
- Analyst Rating Upgrade: Wolfe Research analyst Kalpit Patel upgraded Corcept's rating from underperform to peerperform, primarily based on the FDA approval, although he remains cautious about the growth potential of its other drug, Korlym, reflecting a nuanced view of the company's product lineup.
- Market Potential Outlook: The success of Lifyorli not only provides Corcept with a marketable drug but also validates its unique development approach, particularly in the high-demand cancer treatment sector, potentially laying a solid foundation for future growth.
See More
